Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Regulatory News (HAYD)

Share Price Information for Haydale (HAYD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.385
Bid: 0.37
Ask: 0.40
Change: 0.00 (0.00%)
Spread: 0.03 (8.108%)
Open: 0.385
High: 0.385
Low: 0.385
Prev. Close: 0.385
HAYD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

20 May 2024 07:00

RNS Number : 9902O
Haydale Graphene Industries PLC
20 May 2024
 

For immediate release

20 May 2024

 

Haydale Graphene Industries plc

 

('Haydale', the 'Company', or the 'Group')

Trading Update

 

Haydale, (AIM: HAYD), the global advanced materials group, announces a trading update for the year ending 30 June 2024 (the "Year").

 

The Group anticipates announcing revenues for the Year of £4.7m, behind current market expectations of £5.8m, but still showing growth on the prior year performance of £4.3m. Notwithstanding the reduction in turnover, Adjusted EBITDA is expected to only be marginally behind market expectations, at a £3.15m loss (currently a loss of £3.0m).

 

As reported in the half year interims, the building blocks to take the US silicon carbide business up the value chain and into tooling manufacture and sales have largely been completed, however orders at volume are taking longer than anticipated to crystallise. In addition, certain sales for Q4 have been impacted by a very short term US supply chain issue that will impact on the Company's SiC whisker production in June, reducing available stock.

 

As high value specialist commodity products, the sales cycle for tooling is relatively straightforward based on product performance and cost compared with the incumbent product with no obstacles to switching. Whilst Haydale is starting to see good progress with both late stage pipeline and client accounts increasing, the testing cycle is proving to be longer than anticipated. The Company is currently in testing with a number of major potential tooling customers that it anticipates will make a major difference to the business' performance in a relatively short timeframe with progressive improvement expected as they move forwards. Arrangements with our potential Asia based manufacturing and distribution partner, as referred to in the interims statement, have continued to progress positively and the Directors expect these to now close in H1 FY25. These significant opportunities support the anticipated major growth forecast for FY25, after taking account of the latent start. The Directors therefore anticipate forecast expectations for FY25 to still show major growth on FY24, albeit from the lower starting position.

 

Conversely, the nanomaterial operations centred in the UK have continued to strengthen with continuing growth in the demand for Haydale's functionalisation processes as the industry matures. The Company has seen a continuing stream of projects arising from its existing customer base with major new customers continuing to be added. The Company anticipates these paid for development projects will result in longer term repeat revenues.

 

The Directors expect the general commercial momentum from this Year to continue and accelerate next financial year reflecting building confidence in the medium and long-term prospects and the overall significant potential for the Group

 

For further information:

Haydale Graphene Industries plc

 

Keith Broadbent, CEO

Tel: +44 (0) 1269 842 946

 Patrick Carter, CFO

www.haydale.com 

 

Cavendish Capital Markets Limited (Nominated Adviser & Broker)

Julian Blunt/Edward Whiley, Corporate FinanceAndrew Burdis, ECM

Tel: +44 (0) 20 7220 0500

 

 

 

Notes to Editors

 

Haydale is a global technologies and materials group that facilitates the integration of graphene and other nanomaterials into the next generation of commercial technologies and industrial materials. With expertise in graphene, silicon carbide and other nanomaterials, Haydale can deliver improvements in electrical, thermal, and mechanical properties, as well as toughness through its state-of-the-art functionalisation. Haydale has granted patents for its technologies in Europe, USA, Australia, Japan, and China and operates from five sites in the UK, USA and the Far East.

 

For more information please visit: www.haydale.com

 

LinkedIn: Haydale-ltdX: @haydalegraphene

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFEREDIDLIS
Date   Source Headline
20th May 20247:00 amRNSTrading Update
2nd May 20247:00 amRNSGrant of Share Options and PDMR Dealing
12th Mar 20247:00 amRNSInterim Results
26th Jan 20247:00 amRNSGrant of Options & Surrender of Existing Options
22nd Jan 20247:00 amRNSHaydale selected for Innovate UK Scaleup Programme
7th Dec 202311:36 amRNSResult of AGM
7th Dec 202311:34 amRNSDirectorate Change
6th Dec 20237:00 amRNSHaydale awarded SMART funding
16th Nov 20232:31 pmRNSHolding(s) in Company
13th Nov 20237:00 amRNSPosting of Annual Report & Notice of AGM
1st Nov 20237:00 amRNSTotal Voting Rights
26th Oct 20237:00 amRNSFinal Results
9th Oct 20238:23 amRNSHolding(s) in Company
5th Oct 20231:43 pmRNSDirector/PDMR Shareholding & Total Voting Rights
4th Oct 20234:46 pmRNSHolding(s) in Company
3rd Oct 20233:48 pmRNSResult of General Meeting
2nd Oct 20237:00 amRNSTotal Voting Rights
22nd Sep 20234:30 pmRNSResult of Retail Offer and Total Voting Rights
15th Sep 20236:12 pmRNSResult of Fundraising
15th Sep 20234:00 pmRNSLaunch of Retail Offer
15th Sep 20233:00 pmRNSProposed Placing, Subscription & Retail Offer
15th Sep 20237:00 amRNSWarrant Expiry, Block Admission Cancellation & TVR
22nd Aug 20237:00 amRNSCollaboration with PETRONAS
4th Aug 20231:02 pmRNSHolding(s) in Company
2nd Aug 20237:00 amRNSDirectorate Change
24th Jul 20237:00 amRNSContract Award
13th Jul 20237:00 amRNSHaydale Delivers LPHW Prototype for Cadent
21st Jun 20237:00 amRNSTrading Update
5th Jun 20237:00 amRNSDirectorate Change
24th May 20237:00 amRNSHaydale to Contribute to the Development of FCHEVs
3rd May 20237:00 amRNSSMART Innovation to Accelerate Graphene Products
26th Apr 20233:06 pmRNSGrant of Share Options
12th Apr 20237:00 amRNSHaydale and Saint-Gobain Collaborate on hBN
16th Mar 20237:00 amRNSHaydale and City Energy Develop UFH with Plumbase
14th Mar 20238:15 amRNSBlock listing Interim Review
10th Mar 202311:05 amRNSSecond Price Monitoring Extn
10th Mar 202311:00 amRNSPrice Monitoring Extension
10th Mar 20237:00 amRNSDirectorate Change
1st Mar 20237:00 amRNSInterim Results
28th Feb 202311:38 amRNSHaydale and GEIC Proud to Partner for a Sixth Year
21st Feb 20237:00 amRNSRega Turns to Graphene to Improve Sound Quality
14th Feb 20237:00 amRNSInnovate UK Grant to Image 2D Materials Awarded
7th Feb 20237:00 amRNSHaydale Paddles Forward with Norse Kayaks
30th Jan 20237:00 amRNSNotice of Interim Results
26th Jan 20237:00 amRNSCeramycGuard™ on Trial with United Utilities
20th Dec 20227:00 amRNSGraphene-Enhanced Prepreg Extends Tool Life
1st Dec 20227:00 amRNSFinalist for Collaborate to Innovate Awards
30th Nov 20229:22 amRNSGrant of Warrants
29th Nov 20221:55 pmRNSResult of AGM
15th Nov 20227:00 amRNSGrant of share options and PDMR dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.